Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > Meloxicam Nanocrystal Injection Obtains Clinical Trial Approval

Meloxicam Nanocrystal Injection Obtains Clinical Trial Approval

January 05, 2023

MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL

MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL

Previous: levidipine Injectable Emulsion Obtains Clinical Approval

Next: Highly Selective Prmt5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat